{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T16:20:12Z","timestamp":1707927612803},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1985,9,1]],"date-time":"1985-09-01T00:00:00Z","timestamp":494380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1985,9,1]],"date-time":"1985-09-01T00:00:00Z","timestamp":494380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1985,9]]},"DOI":"10.1007\/bf00179436","type":"journal-article","created":{"date-parts":[[2004,8,22]],"date-time":"2004-08-22T05:07:21Z","timestamp":1093151241000},"page":"303-305","source":"Crossref","is-referenced-by-count":6,"title":["A phase II study of spirogermanium in patients with metastatic malignant melanoma"],"prefix":"10.1007","volume":"3","author":[{"given":"Elizabeth","family":"Eisenhauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audley","family":"Bodurtha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neill","family":"Iscoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Quirt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00179436_CR1","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/jhet.5570110634","volume":"11","author":"LM Rice","year":"1974","unstructured":"Rice LM, Wheeler JW, Geschickter CF: Spirons XXII. Synthesis of 4,4-dialkyl-4-germacyclohexane and 8,8-dialkyl-8 germa-azaspiro (4.5) decanes. J Heterocyclic Chem 11:1041\u20131046, 1974","journal-title":"J Heterocyclic Chem"},{"key":"BF00179436_CR2","first-page":"436","volume":"20","author":"PV Woolley","year":"1979","unstructured":"Woolley PV, Maguire P, Fox P, Hoth D, Slavik M, Schein P: Studies with the anti-tumour agent spirogermanium. Proc Am Assoc Cancer Res 20:436, 1979","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00179436_CR3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00208894","volume":"1","author":"M Slavik","year":"1983","unstructured":"Slavik M, Blanc O, Davis J: Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity. Invest New Drugs 1:225\u2013234, 1983","journal-title":"Invest New Drugs"},{"key":"BF00179436_CR4","first-page":"1051","volume":"64","author":"PS Schein","year":"1980","unstructured":"Schein PS, Slavik M, Smyth T, Hoth D, Macdonald JS, Woolley PV: Phase I clinical trial of spirogermanium. Cancer Treat Rep 64:1051\u20131056, 1980","journal-title":"Cancer Treat Rep"},{"key":"BF00179436_CR5","first-page":"174","volume":"1","author":"DH Gesme","year":"1982","unstructured":"Gesme DH, Vogelzang NJ, Ryan M, Kennedy BJ: Phase I\u2013II study of spirogermanium in advanced neoplastic disease (Abstract). Proc Am Soc Clin Oncol 1:174, 1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF00179436_CR6","first-page":"16","volume":"1","author":"JA Asani","year":"1982","unstructured":"Asani JA, Legha SL, Burgess MA, Bodey GP: Phase I study of spirogermanium (SPG) given for five consecutive days per week (Abstract). Proc Am Soc Clin Oncol 1:16, 1982","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00179436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00179436\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00179436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00179436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T06:36:03Z","timestamp":1682750163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00179436"}},"subtitle":["An NCI Canada Clinical Trials Group study"],"short-title":[],"issued":{"date-parts":[[1985,9]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1985,9]]}},"alternative-id":["BF00179436"],"URL":"https:\/\/doi.org\/10.1007\/bf00179436","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,9]]}}}